CA2076023A1 - Utilisation de la 5-trans-prostaglandine f2a en tant qu'agent hypotenseur oculaire - Google Patents

Utilisation de la 5-trans-prostaglandine f2a en tant qu'agent hypotenseur oculaire

Info

Publication number
CA2076023A1
CA2076023A1 CA002076023A CA2076023A CA2076023A1 CA 2076023 A1 CA2076023 A1 CA 2076023A1 CA 002076023 A CA002076023 A CA 002076023A CA 2076023 A CA2076023 A CA 2076023A CA 2076023 A1 CA2076023 A1 CA 2076023A1
Authority
CA
Canada
Prior art keywords
trans
pgf2
ocular
alpha
prostaglandin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002076023A
Other languages
English (en)
Inventor
David Frederick Woodward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2076023A1 publication Critical patent/CA2076023A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002076023A 1990-03-19 1991-02-12 Utilisation de la 5-trans-prostaglandine f2a en tant qu'agent hypotenseur oculaire Abandoned CA2076023A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49687990A 1990-03-19 1990-03-19
US496,879 1990-03-19

Publications (1)

Publication Number Publication Date
CA2076023A1 true CA2076023A1 (fr) 1991-09-20

Family

ID=23974569

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002076023A Abandoned CA2076023A1 (fr) 1990-03-19 1991-02-12 Utilisation de la 5-trans-prostaglandine f2a en tant qu'agent hypotenseur oculaire

Country Status (7)

Country Link
EP (1) EP0521009A4 (fr)
JP (1) JPH05505605A (fr)
CA (1) CA2076023A1 (fr)
FI (1) FI924205A0 (fr)
HU (1) HUT61666A (fr)
IE (1) IE910865A1 (fr)
WO (1) WO1991014428A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468778A (en) * 1992-09-24 1995-11-21 Allergan, Inc. Method of lowering intraocular pressure by administering a pharmaceutical composition containing 7-(5-substituted cyclopentyl) and 7-(5-substituted-cyclopentenyl) 5-heptenoic acids and derivatives
EP0664707B1 (fr) * 1992-10-13 1997-06-04 Alcon Laboratories, Inc. Combinaisons de prostaglandines et de derives de clonidine pour le traitement du glaucome
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US6414021B1 (en) * 2000-08-25 2002-07-02 Sucampo Ag Control of intraocular pressure during surgery
EP1671593B1 (fr) 2002-10-04 2008-02-27 Tyco Healthcare Group Lp Ensemble outil pour agrafeuse chirurgicale

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA715163B (en) * 1970-09-15 1972-04-26 Upjohn Co Prostanoic acid derivatives
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
SE8703854D0 (sv) * 1987-10-07 1987-10-07 Pharmacia Ab Prostaglandinderivat for behandling av glaukom eller okuler hypertension

Also Published As

Publication number Publication date
WO1991014428A1 (fr) 1991-10-03
HUT61666A (en) 1993-03-01
HU9202572D0 (en) 1992-12-28
JPH05505605A (ja) 1993-08-19
FI924205A (fi) 1992-09-18
IE910865A1 (en) 1991-09-25
EP0521009A4 (en) 1993-02-24
FI924205A0 (fi) 1992-09-18
EP0521009A1 (fr) 1993-01-07

Similar Documents

Publication Publication Date Title
US10045997B2 (en) Hypotensive lipid and timolol compositions and methods of using same
AU685591B2 (en) EP2-receptor agonists as agents for lowering intraocular pressure
AU2002312221A1 (en) Hypotensive lipid (prostaglandin derivatives) and timolol compositions and methods of using same
US20110275711A1 (en) Method for treating macular edema
US20070049625A1 (en) EP2 receptor agonists for treating glaucoma
CA2076023A1 (fr) Utilisation de la 5-trans-prostaglandine f2a en tant qu'agent hypotenseur oculaire
JP2000511530A (ja) 高眼圧処置用の医薬としてのシクロペンタン（エン）酸，２―アルケニル誘導体
ES2358558T3 (es) Derivados de tiofeno como medicamentos para el tratamiento de la hipertensión ocular.
EP0527748B1 (fr) Emploi de prostaglandine F3alpha comme agent oculaire hypertensif
AU644422B2 (en) Use of 5-trans prostaglandin f2 alpha as an ocular hypotensive agent
AU644642B2 (en) Use of prostaglandin f3 alpha as an ocular hypotensive agent
US5194449A (en) Use of prostaglandin F3α as an ocular hypotensive agent
WO2007011720A2 (fr) Composes de cyclopentane n alkyle inferieur heptenamide-5-cis-2- (3a- hydroxy-5-phenylpentyl) -3, 5-dihydroxy, [1a,2b,3a,5a] utilises en tant qu'agents d'abaissement de la pression intraoculaire
US6124353A (en) Method of treating ocular hypertension with 8-epi prostaglandins
AU2010202674B2 (en) Hypotensive lipid and timolol compositions and methods of using same
JPH1171272A (ja) 角膜新生血管増殖抑制剤
AU2014201651A1 (en) Hypotensive lipid and timolol compositions and methods of using same

Legal Events

Date Code Title Description
FZDE Dead